Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

irinotecan sucrosofate 1Taxes 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Pancreatic Cancer Non-resectable × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡